Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
OVERLAP
20%
OVERLAP
BY WEIGHT
11
# OF OVERLAPPING
HOLDINGS
FTXH
51
HOLDINGS
23%
ALSO IN CANC
CANC
51
HOLDINGS
22%
ALSO IN FTXH
SECTOR DRIFT (FTXH minus CANC)
OVERLAPPING HOLDINGS
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in FTXH |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
| ELI LILLY & CO | 3.9% | 5.3% | 3.9% | |
| BRISTOL-MYERS SQUIBB CO | 6.4% | 2.5% | 2.5% | |
| ABBVIE INC | 7.5% | 2.5% | 2.5% | |
| GILEAD SCIENCES INC | 3.7% | 2.5% | 2.5% | |
| JOHNSON & JOHNSON | 7.4% | 2.0% | 2.0% | |
FTXH Overweight Relative to CANC
| PFIZER INC | 6.9% | |
| MERCK & CO. INC. | 5.6% | |
| JOHNSON & JOHNSON | 5.4% | |
| ABBVIE INC | 5.0% | |
| BRISTOL-MYERS SQUIBB CO | 3.9% | |
| BIOGEN IDEC INC | 3.8% | |
| CARDINAL HEALTH INC | 3.7% | |
| VERTEX PHARMACEUTICALS INC | 3.7% | |
| VIATRIS, INC. | 3.4% | |
| UNITED THERAPEUTICS CORP | 3.2% |
FTXH Underweight Relative to CANC
| REVOLUTION MEDICINES, INC. | -7.0% | |
| ROCHE HOLDINGS LTD-SPONS ADR | -4.2% | |
| NOVARTIS AG | -4.2% | |
| GENMAB A/S SPONSORED ADR | -4.1% | |
| ASTRAZENECA PLC | -4.1% | |
| ARCELLX, INC. | -3.7% | |
| NUVALENT, INC. CLASS A | -3.7% | |
| BRIDGEBIO PHARMA, INC. | -3.4% | |
| MERUS N.V. | -2.7% | |
| IDEAYA BIOSCIENCES, INC. | -2.6% |